Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial
ERBB2阳性乳腺癌新辅助治疗:一项3期随机临床试验
期刊:Jama Oncology
影响因子:23.900
doi:10.1001/jamaoncol.2026.3329
Li, Junjie; Liu, Tong; Yu, Ke-Da; Yang, Huawei; Huang, Zhen; Zeng, Yi; Ji, Peng; Hou, Xiaoke; Liu, Chunping; Zhang, Yiwen; Li, Nanlin; Ouyang, Zhong; Wu, Xiaobo; Bai, Xiaorong; Guo, Yanxiang; Han, Guohui; Cui, Shien; Zhu, Zhijun; Zhang, Yu; Hu, Xiaobo; Ma, Xiaopeng; Fu, Peifen; Zhu, Jinhai; Dong, Yuan; Wu, Tao; Jia, Hongyan; Xu, Fei; Ren, Yu; Nie, Jianyun; Bing, Dai; Mu, Qiang; Sun, Tao; Luo, Jing; Song, Zhenchuan; Kong, Xiangshun; Zhang, Hao; Wu, Zhiyong; Wang, Zhihong; Song, Dong; Jia, Haiquan; Tao, Wei; Fan, Pingming; Yao, Fan; Ru, Chen; Lai, Guie; Zhou, Xin; Li, Taolang; Deng, Chao; Jiang, Xuemei; Wang, Xiaochun; Wang, Jingfen; Xiong, Dun; Zhang, Shuqun; Yang, Hongwei; Yao, Yongzhong; Yin, Guobing; Yao, Guangyu; Zhou, Li; Wang, Shu; Yu, Zhigang; Yu, Yang; Lv, Ye; Qian, Hesheng; Li, Huiping; Guo, Wenhui; Huang, Wei; Xiang, Silong; Zou, Kai; He, Hang; Fan, Lei; Shao, Zhi-Ming